Literature DB >> 31741236

Novel nonsense IL-12Rβ1 mutation associated with recurrent tuberculosis.

Noor Ul Akbar1, Shahid Niaz Khan1, Muhammad Usman Amin2, Muhammad Ishfaq3, Otavio Cabral-Marques4, Lena F Schimke4, Asif Iqbal5, Ikram Ullah6, Mubashir Hussain7, Ijaz Ali8, Nasar Khan9, Nadia El Khawanky10,11, Hazir Rahman12, Taj Ali Khan13.   

Abstract

The interleukin (IL)-12/interferon(IFN)γ axis plays an important role in the control of mycobacterial diseases as demonstrated by the increased susceptibility to mycobacterial species in patients with an inborn error of the IL-12-dependent IFNγ immunity. Here, we report a novel mutation in the IL-12Rβ1 gene in a female Pakistani patient who was born in a consanguineous marriage and developed severe bacille Calmette-Guérin (BCG) infection and recurrent tuberculosis. After reviewing the patient's clinical records, she was investigated for IL-12/IFNγ defects using enzyme-linked immunosorbent assay (ELISA), flow cytometry, and DNA genetic Sanger sequencing. Quantification of secretory cytokines from the patient's peripheral blood mononuclear cells (PBMCs) revealed significantly reduced IFNγ production. Flow cytometric analysis revealed no surface expression of IL-12Rβ1 on PHA-activated T lymphocytes. In addition, IL-12-induced impaired STAT4 phosphorylation in the patient's lymphocytes when compared with those from five healthy controls. The genetic analysis of IL-12Rβ1 gene identified a novel nonsense mutation c.199G>T/p.E67* within exon 3, which encodes part of the cytokine-binding region (CBR). In silico analysis indicates that this novel nonsense mutation generates a truncated protein with an apparent inactivating effect. Our data expand the genetic spectrum of IL-12Rβ1 deficiency. Moreover, our findings highlight the need for developing newborn screening for patients with primary immunodeficiency associated with mycobacterial infections in areas where BCG vaccination is mandatory in order to improve the treatment of patients, and consequently their quality of life.

Entities:  

Keywords:  IFNγ; IL-12Rβ1; Novel mutation; Tuberculosis

Mesh:

Substances:

Year:  2019        PMID: 31741236     DOI: 10.1007/s12026-019-09094-8

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  41 in total

1.  First report of the Hyper-IgM syndrome Registry of the Latin American Society for Immunodeficiencies: novel mutations, unique infections, and outcomes.

Authors:  Otavio Cabral-Marques; Stefanie Klaver; Lena F Schimke; Évelyn H Ascendino; Taj Ali Khan; Paulo Vítor Soeiro Pereira; Angela Falcai; Alexander Vargas-Hernández; Leopoldo Santos-Argumedo; Liliana Bezrodnik; Ileana Moreira; Gisela Seminario; Daniela Di Giovanni; Andrea Gómez Raccio; Oscar Porras; Cristina Worm Weber; Janaíra Fernandes Ferreira; Fabiola Scancetti Tavares; Elisa de Carvalho; Claudia França Cavalcante Valente; Gisele Kuntze; Miguel Galicchio; Alejandra King; Nelson Augusto Rosário-Filho; Milena Baptistella Grota; Maria Marluce dos Santos Vilela; Regina Sumiko Watanabe Di Gesu; Simone Lima; Leiva de Souza Moura; Eduardo Talesnik; Eli Mansour; Pérsio Roxo-Junior; Juan Carlos Aldave; Ekaterine Goudouris; Fernanda Pinto-Mariz; Laura Berrón-Ruiz; Tamara Staines-Boone; Wilmer O Córdova Calderón; María del Carmen Zarate-Hernández; Anete S Grumach; Ricardo Sorensen; Anne Durandy; Troy R Torgerson; Beatriz Tavares Costa Carvalho; Francisco Espinosa-Rosales; Hans D Ochs; Antonio Condino-Neto
Journal:  J Clin Immunol       Date:  2014-01-09       Impact factor: 8.317

2.  Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients.

Authors:  R de Jong; F Altare; I A Haagen; D G Elferink; T Boer; P J van Breda Vriesman; P J Kabel; J M Draaisma; J T van Dissel; F P Kroon; J L Casanova; T H Ottenhoff
Journal:  Science       Date:  1998-05-29       Impact factor: 47.728

Review 3.  Immune defects in active mycobacterial diseases in patients with primary immunodeficiency diseases (PIDs).

Authors:  Wen-I Lee; Jing-Long Huang; Kuo-Wei Yeh; Tang-Her Jaing; Tzou-Yien Lin; Yhu-Chering Huang; Cheng-Hsun Chiu
Journal:  J Formos Med Assoc       Date:  2011-12-23       Impact factor: 3.282

Review 4.  Innate defects of the IL-12/IFN-γ axis in susceptibility to infections by mycobacteria and salmonella.

Authors:  Noé Ramirez-Alejo; Leopoldo Santos-Argumedo
Journal:  J Interferon Cytokine Res       Date:  2013-12-20       Impact factor: 2.607

5.  The World Health Organization standards for tuberculosis care and management.

Authors:  Christopher Gilpin; Alexei Korobitsyn; Giovanni Battista Migliori; Mario C Raviglione; Karin Weyer
Journal:  Eur Respir J       Date:  2018-03-22       Impact factor: 16.671

6.  BCG vaccination is associated with decreased severity of tuberculosis in Pakistan.

Authors:  Zahra Hasan; Muhammad Irfan; Javaid A Khan; Shehryar Khaliqdina Jahangir; Muhammad Haris; Mussarat Ashraf; Naseem Salahuddin; Bushra Jamil; Nisar A Rao
Journal:  Int J Mycobacteriol       Date:  2012-11-15

7.  Novel RAG1 mutation and the occurrence of mycobacterial and Chromobacterium violaceum infections in a case of leaky SCID.

Authors:  Taj Ali Khan; Asif Iqbal; Hazir Rahman; Otavio Cabral-Marques; Muhammad Ishfaq; Noor Muhammad
Journal:  Microb Pathog       Date:  2017-05-25       Impact factor: 3.738

Review 8.  The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases.

Authors:  Saleh Al-Muhsen; Jean-Laurent Casanova
Journal:  J Allergy Clin Immunol       Date:  2008-12       Impact factor: 10.793

Review 9.  Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter?

Authors:  William R Berrington; Thomas R Hawn
Journal:  Immunol Rev       Date:  2007-10       Impact factor: 12.988

10.  Adjuvant interferon gamma in patients with drug - resistant pulmonary tuberculosis: a pilot study.

Authors:  Roberto Suárez-Méndez; Idrian García-García; Norma Fernández-Olivera; Magalys Valdés-Quintana; María T Milanés-Virelles; Dalia Carbonell; Delfina Machado-Molina; Carmen M Valenzuela-Silva; Pedro A López-Saura
Journal:  BMC Infect Dis       Date:  2004-10-22       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.